JP4225057B2 - ナテグリニドｂ型結晶の製造方法 - Google Patents

ナテグリニドｂ型結晶の製造方法 Download PDF

Info

Publication number
JP4225057B2
JP4225057B2 JP2002537707A JP2002537707A JP4225057B2 JP 4225057 B2 JP4225057 B2 JP 4225057B2 JP 2002537707 A JP2002537707 A JP 2002537707A JP 2002537707 A JP2002537707 A JP 2002537707A JP 4225057 B2 JP4225057 B2 JP 4225057B2
Authority
JP
Japan
Prior art keywords
crystals
nateglinide
type
producing
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002537707A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2002034713A1 (ja
Inventor
通人 澄川
誠 丸尾
和雄 宮崎
重宏 仁科
由紀子 松澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of JPWO2002034713A1 publication Critical patent/JPWO2002034713A1/ja
Application granted granted Critical
Publication of JP4225057B2 publication Critical patent/JP4225057B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002537707A 2000-10-24 2001-10-23 ナテグリニドｂ型結晶の製造方法 Expired - Fee Related JP4225057B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000324375 2000-10-24
JP2000324375 2000-10-24
PCT/JP2001/009293 WO2002034713A1 (en) 2000-10-24 2001-10-23 Process for producing b-form nateglinide crystal

Publications (2)

Publication Number Publication Date
JPWO2002034713A1 JPWO2002034713A1 (ja) 2004-03-04
JP4225057B2 true JP4225057B2 (ja) 2009-02-18

Family

ID=18801920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002537707A Expired - Fee Related JP4225057B2 (ja) 2000-10-24 2001-10-23 ナテグリニドｂ型結晶の製造方法

Country Status (18)

Country Link
US (2) US20030229249A1 (OSRAM)
EP (1) EP1334964B1 (OSRAM)
JP (1) JP4225057B2 (OSRAM)
KR (1) KR100810930B1 (OSRAM)
CN (1) CN100422143C (OSRAM)
AT (1) ATE370115T1 (OSRAM)
AU (1) AU2001296001A1 (OSRAM)
BR (1) BR0114846A (OSRAM)
CA (1) CA2426745C (OSRAM)
CY (1) CY1106839T1 (OSRAM)
DE (1) DE60130014T2 (OSRAM)
DK (1) DK1334964T3 (OSRAM)
ES (1) ES2288997T3 (OSRAM)
MX (1) MXPA03003575A (OSRAM)
PT (1) PT1334964E (OSRAM)
RU (1) RU2275354C2 (OSRAM)
TW (1) TWI293290B (OSRAM)
WO (1) WO2002034713A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003087039A1 (ja) * 2002-04-15 2005-08-18 味の素株式会社 新規ナテグリニド結晶
US7888531B2 (en) 2002-04-15 2011-02-15 Ajinomoto Co., Inc. Nateglinide crystals

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0109336A (pt) * 2000-03-17 2003-06-24 Ajinomoto C0 Inc Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
RU2287520C2 (ru) * 2000-10-18 2006-11-20 Адзиномото Ко., Инк. Способ получения ацилфенилаланинов
AU2001294265A1 (en) * 2000-10-18 2002-04-29 Ajinomoto Co., Inc. Process for producing nateglinide crystal
DK1334720T3 (da) * 2000-10-24 2009-01-19 Ajinomoto Kk Nateglinid-indeholdende fremstillinger
DE60138476D1 (de) * 2000-10-24 2009-06-04 Ajinomoto Kk Nateglinid enthaltende hydrophile arzneimittelpräparate
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
JP2006511614A (ja) * 2002-07-18 2006-04-06 テバ ファーマシューティカル インダストリーズ リミティド ナテグリニドの多形性形状
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) * 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
EP1535900B1 (en) * 2003-11-26 2006-12-27 A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.p.A. Process for the preparation of nateglinide, preferably in b-form
KR20080086937A (ko) * 2004-05-07 2008-09-26 테바 파마슈티컬 인더스트리즈 리미티드 나테글리나이드의 다형태
US20070231393A1 (en) * 2004-05-19 2007-10-04 University Of South Carolina System and Device for Magnetic Drug Targeting with Magnetic Drug Carrier Particles
US20080096970A1 (en) * 2004-05-20 2008-04-24 Sundaram Venkataraman Stable Nateglinide Form B Compositions
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
WO2006080524A1 (ja) * 2005-01-31 2006-08-03 Ajinomoto Co., Inc. 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物
WO2007135533A1 (en) * 2006-05-23 2007-11-29 Aurobindo Pharma Limited Process for preparing nateglinide b-type crystals
KR100837843B1 (ko) * 2006-12-26 2008-06-13 씨제이제일제당 (주) 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물
WO2011157986A1 (en) 2010-06-14 2011-12-22 Cipla Limited A process for the preparation of nateglinide
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
EP2847161A4 (en) * 2012-05-08 2015-12-23 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR TREATING DIABETES
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
CN104583182A (zh) 2012-05-23 2015-04-29 塞利克斯比奥私人有限公司 用于治疗粘膜炎的组合物和方法
SG11201407322QA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of multiple sclerosis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
AU2013264894B2 (en) 2012-05-23 2015-11-19 Cellix Bio Private Limited Compositions and methods for treatment of inflammatory bowel disease
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (en) 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en) 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
SG11201702554QA (en) 2014-09-29 2017-04-27 Cellix Bio Private Ltd Compositions and methods for the treatment of multiple sclerosis
SG11201703369WA (en) 2014-10-27 2017-05-30 Cellix Bio Private Ltd Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
CN104402756B (zh) * 2014-11-27 2016-08-31 天方药业有限公司 一种高纯度那格列奈的制备方法
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
CN109369443A (zh) * 2018-11-05 2019-02-22 扬子江药业集团江苏海慈生物药业有限公司 一种新的那格列奈h晶型的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
AU615966B2 (en) * 1987-12-04 1991-10-17 Takeda Chemical Industries Ltd. Crystals of cephem hydrochloride
ATE149483T1 (de) * 1991-07-30 1997-03-15 Ajinomoto Kk Kristalle von n-(trans-4- isopropylcyclohexylcarbonyl)-d-phenylalanin und verfahren zu ihrer herstellung
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
WO1998022105A1 (en) * 1996-11-15 1998-05-28 Ajinomoto Co., Inc. Tabletted preparation
US6844006B1 (en) * 1999-07-09 2005-01-18 Pennfield Oil Company Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions
ES2305977T3 (es) * 1999-12-28 2008-11-01 Ajinomoto Co., Inc. Preparacion antidiabetica para administracion oral.
BR0109336A (pt) * 2000-03-17 2003-06-24 Ajinomoto C0 Inc Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
AU2001294265A1 (en) * 2000-10-18 2002-04-29 Ajinomoto Co., Inc. Process for producing nateglinide crystal
RU2287520C2 (ru) * 2000-10-18 2006-11-20 Адзиномото Ко., Инк. Способ получения ацилфенилаланинов
DK1334720T3 (da) * 2000-10-24 2009-01-19 Ajinomoto Kk Nateglinid-indeholdende fremstillinger
US7411089B2 (en) * 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003087039A1 (ja) * 2002-04-15 2005-08-18 味の素株式会社 新規ナテグリニド結晶
JP2010090174A (ja) * 2002-04-15 2010-04-22 Ajinomoto Co Inc 新規ナテグリニド結晶
JP4538842B2 (ja) * 2002-04-15 2010-09-08 味の素株式会社 新規ナテグリニド結晶
US7888531B2 (en) 2002-04-15 2011-02-15 Ajinomoto Co., Inc. Nateglinide crystals
US7977507B2 (en) 2002-04-15 2011-07-12 Ajinomoto Co., Inc. Nateglinide crystals

Also Published As

Publication number Publication date
CY1106839T1 (el) 2012-05-23
DE60130014T2 (de) 2008-05-08
CN1483018A (zh) 2004-03-17
RU2275354C2 (ru) 2006-04-27
EP1334964B1 (en) 2007-08-15
MXPA03003575A (es) 2003-07-14
US7544834B2 (en) 2009-06-09
EP1334964A4 (en) 2005-09-28
CA2426745C (en) 2009-09-15
CN100422143C (zh) 2008-10-01
JPWO2002034713A1 (ja) 2004-03-04
WO2002034713A1 (en) 2002-05-02
TWI293290B (OSRAM) 2008-02-11
KR20030059212A (ko) 2003-07-07
US20070232829A1 (en) 2007-10-04
AU2001296001A1 (en) 2002-05-06
DE60130014D1 (de) 2007-09-27
KR100810930B1 (ko) 2008-03-10
CA2426745A1 (en) 2003-04-23
ATE370115T1 (de) 2007-09-15
DK1334964T3 (da) 2007-09-24
BR0114846A (pt) 2004-02-25
EP1334964A1 (en) 2003-08-13
PT1334964E (pt) 2007-09-20
ES2288997T3 (es) 2008-02-01
US20030229249A1 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
JP4225057B2 (ja) ナテグリニドｂ型結晶の製造方法
US6022985A (en) Process for the preparation of 4-acetoxy-2α-benzoyloxy-5β, 20-epoxy-1, 7β-10β-trihydroxy-9-oxo-tax-11-en-13α-yl(2R,3S)-3-tert-b utoxy-carbonYlamino-2-hydroxy-3-phenylpropionate trihydrate
KR920000648B1 (ko) α-L-아스파르틸-L-페닐알라닌 메틸 에스테르의 분리방법
JPS61293949A (ja) ａ−イソプロピル−ｐ−クロルフエニル酢酸の光学分割法
CN115989212A (zh) 用于合成无水乳酸的方法
JP2025041833A (ja) 結晶形ｉｉのソタグリフロジンを調製する方法
JP7595064B2 (ja) 結晶形ｉｉのソタグリフロジンを連続的に調製する方法
TW202304867A (zh) 經取代二胺基吡𠯤二羧酸之純化
US2456742A (en) Separation of isomers of amino acids
JP2004256448A (ja) ６−ヒドロキシ−２−ナフトエ酸の脱色方法
JPS6041676B2 (ja) Ｓ−２−（３−アミノプロピルアミノ）エチルジハイドロジエンホスホロチオエ−ト１水和結晶の新規製法
JP4397990B2 (ja) ３−アルキルフラバノノール誘導体の精製法
JP2957273B2 (ja) ７―クロル―キノリン―８―カルボン酸の精製方法
JPS597142A (ja) γ型グリシンの製造方法
JP3923798B2 (ja) フマギリンの調製プロセス
CN112585122B (zh) 用于制备1,4-脱水山梨糖醇的方法
JPH0219365A (ja) ジスルフィド型サイアミン誘導体の無機酸塩の製造法
JP4694018B2 (ja) メバロラクトンメタクリル酸エステルの精製方法
CN119798107A (zh) 一种dl-泛醇的制备方法
JPS62294637A (ja) 粗イブプロフエンの精製方法
JP3191456B2 (ja) カルボン酸一無水物の製造方法
JPH1036350A (ja) ４−ヒドロキシピペリジンの精製方法
JPH0472824B2 (OSRAM)
JPS585911B2 (ja) （ ２− オキソ − ピロリジン −１ ） − アセトアミド ノ セイゾウホウホウ
JPS63139181A (ja) ２−（１０，１１−ジヒドロ−１０−オキソジベンゾ〔ｂ，ｆ〕チエピン−２−イル）プロピオン酸の結晶化方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081104

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081117

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111205

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111205

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111205

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121205

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121205

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131205

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees